the lack of compliance with the guidelines set by the European hypertension guidelines interfere with the proper treatment of the hypertensive. patients
according to the findings of the survey SHARE, which publishes Journal of Hypertension.
-poll, in which participated 2.629 doctors in primary care and specialists from all over Europe, part of HypertensionCare, the initiative of Daiichi Sankyo that combines medicines, services and knowledge to hypertension.
Madrid, July 2011.-health professionals do not treat in a systematic manner their patients according to the targets posed by European societies hypertension guidelines hypertension and Cardiology (ESH-ESC, according to its English acronym). This is one of the main findings of the survey SHARE (Supporting Hypertension Awareness & Research Europe-wide, i.e. support for awareness-raising and research on hypertension in Europe), whose results are published in Journal of Hypertension.
the lack of monitoring by doctors of the guidelines set by the European guidelines is one of the factors that contribute to a greater extent to increase charges associated with hipertensión1, suffering from more than one billion people and disease causing 7.6 million deaths each year. Only in Spain, it is estimated that they suffer from high blood pressure more than 13 million people. If it is not treated properly, this disease can cause serious cardiovascular complications among the heart attack and stroke. Also, the lack of control of hypertension is one of the main factors of health spending and only in Europe is estimated to cardiovascular health cost of more than 190,000 million euros for the year.
main results .
SHARE survey has counted with the participation of 2.629 primary care physicians and specialists throughout Europe. according to the results, 90% of respondents say that they do not take measures against high blood pressure of patients so far that the diastolic blood pressure levels exceed levels recommended by guidelines, a figure that rises to 95 per cent of respondents in the case of systolic blood pressure.
in spite of which 82% European health professionals consider that the objectives of blood pressure of 140/90 mmHg marked by guides ESH-ESC are correct broadly ”, the average blood pressure which are beginning to see grounds for concern-ing is 149/92 mmHgpretty on top of dictating the guides. Moreover, the interviewed doctors consider blood pressure must achieve an average of 168/100 mmHg to feel who must take immediate action.
any patient with blood pressure greater than 140/90 mmHg needs to be addressed properly to reduce his level of hypertension and the risk of cardiovascular disease. To delay treatment, doctors are potentially increasing the possibility of their patients to undergo a cardiovascular event ”, says Professor Roland Schmieder, head of competition unit of clinical research on hypertension and Vascular Medicine of the University Hospital of Erlangen and Professor of internal medicine, Nephrology and hypertensionGermany, and a member of the Organizing Committee of SHARE. Medical, we tend to assume that if the patient does not reach its goals of blood pressure is due to their lack of adherence to treatment, but the survey shows clearly that health professionals also can do more to help our patients achieve their goals of hypertension ”, adds Professor Schmieder.
SHARE aims to understand the challenges faced by health workers in achieving their patients to achieve the proposed objectives of blood pressure. It is an initiative sponsored by European leaders in the field of hypertension with the support of Daiichi Sankyo. SHARE is part of HypertensionCare, the platform through which Daiichi Sankyo provides the occupational health services, knowledge and a broad range of medicines based on olmesartan, with the aim of contributing to effectively combat high blood pressure. For more information about SHARE and HypertensionCare.
about HypertensionCare.
HypertensionCare is the initiative of Daiichi Sankyo to high blood pressure that provides healthcare professionals a wide range of products, services and know-how in order to help them overcome the challenges posed by high pressure in their daily practice. HypertensionCare includes four drugs that offer a wide range of options to prevent the progression of hypertension: Olmetec ®, Olmetec Plus ®, Sevikar ® and Sevikar HCT ®, all of them based on olmesartan. addition products, Daiichi Sankyo provides health professionals with tools and training that allows them to learn more about obstacles which faced in achieving the levels proposed arterial pressure for their patients.
about Daiichi Sankyo.
the Group Daiichi Sankyo is dedicated to the research and supply of innovative pharmaceutical products, both in mature and emerging markets, that address various medical needs of patients who are not yet covered. The company was created in 2005 through the merger of two companies of Japanese tradition and Daiichi Sankyo. Daiichi Sankyo is one of the 20 leading pharmaceutical companies in the world. In addition to the maintenance of its drugs for hypertension, Hyperlipidemia, and bacterial infections, the group is focused on the development of treatments for disorders thrombotic research in Oncology as well as new therapies in the cardiovascular area and metabolism. On the other hand, Daiichi Sankyo group has created a hybrid business model , which responds to the diversity of the market and customer seeking to optimize the opportunities for growth in the entire chain of value.
the company’s global headquarters is located in Tokyo. Its European base, Daiichi Sankyo Europe, is in Munich and has subsidiaries in 12 European countries as well as a plant of global manufacturing in Pfaffenhofen (Germany).
